Literature DB >> 2486428

Amyloidosis in children with familial Mediterranean fever.

H Koçak1, N Beşbaş, U Saatçi, A Bakkaloğlu.   

Abstract

In this survey 113 children with secondary amyloidosis due to familial Mediterranean fever are reviewed in regard to their respective histories, and physical and laboratory findings. The beneficial effects of colchicine in the treatment of this condition are evaluated. The number of children presented with amyloidosis secondary to familial Mediterranean fever was considerable. The male-female ratio was 4/3. It was observed that the number of patients with amyloidosis increased through the adolescent period, and that most of the cases demonstrated phenotype I (74.33%). Another important finding was the increase of partial thromboplastin time in 96 out of 113 cases (84.95%). All the symptoms of the periodic attacks were relieved by colchicine. A significant difference was found between the serum total protein and albumin values before and after colchicine therapy.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2486428

Source DB:  PubMed          Journal:  Turk J Pediatr        ISSN: 0041-4301            Impact factor:   0.552


  3 in total

1.  Hyperimmunoglobulin M syndrome associated with systemic amyloidosis type AA.

Authors:  A Oner; G Demircin; K Tinaztepe; O Pekuz; F Ersoy
Journal:  Eur J Pediatr       Date:  1995-12       Impact factor: 3.183

2.  A survey of phenotype II in familial Mediterranean fever.

Authors:  M Melikoğlu; H Ozdoğan; C Korkmaz; O Kasapçopur; N Arisoy; S Akkuş; Z Fresko; H Yazici
Journal:  Ann Rheum Dis       Date:  2000-11       Impact factor: 19.103

3.  Low serum apolipoprotein AI levels in amyloidosis related to familial Mediterranean fever.

Authors:  Ismail Işlek; Tülin Simşek; Esra Baskin; Behçet Simşek; Sükrü Küçüködük; Abdülkerim Bedir; Ayşin Bakkaloğlu; Nesrin Beşbaş; Rezzan Topaloğlu; Seza Ozen; Umit Saatçi
Journal:  Pediatr Nephrol       Date:  2003-07-23       Impact factor: 3.714

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.